🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Daxing Liu

Loxo Oncology at Lilly (United States)

ORCID: 0000-0001-8532-9611

Materials ScienceBiochemistry, Genetics and Molecular BiologyEngineeringMedicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 3 papers. Top paper: “Design, synthesis, biochemical evaluation, radiolabeling and in vivo imaging with high affinity class-IIa histone deacetylase inhibitor for molecular imaging and targeted therapy”.

Design, synthesis, biochemical evaluation, radiolabeling and in vivo imaging with high affinity class-IIa histone deacetylase inhibitor for molecular imaging and targeted therapy

European Journal of Medicinal Chemistry(2021)10.1016/j.ejmech.2021.114011

N/A

0DataRank · unranked

16 citations

Daxing Liu, Isabella Pirola, Nashaat Turkman

Novel late-stage radiosynthesis of 5-[18F]-trifluoromethyl-1,2,4-oxadiazole (TFMO) containing molecules for PET imaging

Scientific Reports(2021)10.1038/s41598-021-90069-x

N/A

0DataRank · unranked

14 citations

Daxing Liu, Isabella Pirola, Nashaat Turkman

A Lipid Targeting, pH‐Responsive Nanoemulsion Encapsulating a DNA Intercalating Agent and HDAC Inhibitor Reduces TNBC Tumor Burden

Advanced Therapeutics(2021)10.1002/adtp.202000211

N/A

0DataRank · unranked

7 citations

Jacob M. Hebert, Daxing Liu, Debra T. Auguste, Bumjun Kim